Marked [qlco]
Bradykinin [aapp, horm, nsba]
Induced [ftcn]
Tissue Plasminogen Activator [aapp, enzy, phsu]
Release [hlca]
Patients [podg]
Heart failure [dsyn]
Maintained [ftcn]
Long-term [tmco]
Angiotensin converting enzyme inhibitor therapy [topp]
objectives [inpr]
Aim [idcn]
Present [qnco]
Study [mnob]
To [qlco]
Assess [acty]
Contribution [acty]
Angiotensin converting enzyme inhibitor therapy [topp]
Bradykinin [aapp, horm, nsba]
Induced [ftcn]
Tissue-Type Plasminogen Activator [aapp, enzy, phsu]
Release [hlca]
Patients [podg]
Heart failure [dsyn]
secondary [neop]
ischaemic heart disease [dsyn]
Background [cnce]
Bradykinin [aapp, horm, nsba]
Potential [qlco]
Endothelial [tisu]
Cell stimulant [phsu]
Vasodilatation [phsf]
Type [qlco]
Plasminogen Activator [aapp, enzy, phsu]
Release [hlca]
Large [qnco]
Scale [medd]
Clinical Trials [resa]
Angiotensin converting enzyme inhibitor therapy [topp]
PREVENT [phsu]
Ischaemic [ftcn]
Events [evnt]
Methods [inpr]
Nine [qnco]
Patients [podg]
Symptomatic [ftcn]
Heart failure [dsyn]
Evaluated [ftcn]
Two [qnco]
Occasional [tmco]
Following [tmco]
SEVEN-DAY [inpr]
Withdrawal [acty]
Long-term [tmco]
Angiotensin converting enzyme inhibitor therapy [topp]
Forearm [bpoc]
Blood flow [orgf]
Measured [qlco]
Using [ftcn]
Bilateral [spco]
Venous occlusion plethysmography [diap]
Bradykinin [aapp, horm, nsba]
pmol [qnco]
Substance P [aapp, nsba]
pmol [qnco]
Sodium Nitroprusside [orch, phsu]
pmol [qnco]
Venous blood sample [bdsu]
Withdrawn [fndg]
Forearms [bpoc]
estimation [menp]
fibrinolytic [topp]
variables [qlco]
Result [ftcn]
Study Day [tmco]
Bradykinin [aapp, horm, nsba]
Substance P [aapp, nsba]
Dose-dependent [qnco]
Vasodilatation [phsf]
Release [hlca]
Type [qlco]
Plasminogen Activator [aapp, enzy, phsu]
Forearm [bpoc]
P NOS [aapp, imft]
BY [geoa]
Analysis of Variance [qnco]
Long-term [tmco]
Angiotensin converting enzyme inhibitor therapy [topp]
Increase [ftcn]
Forearm [bpoc]
Vasodilatation [phsf]
P NOS [aapp, imft]
BY [geoa]
Analysis of Variance [qnco]
Type [qlco]
Plasminogen Activator [aapp, enzy, phsu]
Release [hlca]
P NOS [aapp, imft]
BY [geoa]
Analysis of Variance [qnco]
Bradykinin [aapp, horm, nsba]
Not [ftcn]
Substance P [aapp, nsba]
Infusion [topp]
Maximal [qlco]
Local [spco]
plasma concentration [qnco]
Type [qlco]
plasminogen activator activity [moft]
Approach [spco]
Maximal [qlco]
Forearm [bpoc]
Protein [aapp, bacs]
Release [hlca]
SIM [gngm]
Mu [inpr]
g/min [qnco]
Conclusions [idcn]
Long-term [tmco]
Angiotensin converting enzyme inhibitor therapy [topp]
augment [qnco]
Bradykinin [aapp, horm, nsba]
Induced vasodilatation [topp]
Peripheral [spco]
Local [spco]
Type [qlco]
Plasminogen Activator [aapp, enzy, phsu]
Release [hlca]
Patients [podg]
Heart failure [dsyn]
ischaemic heart disease [dsyn]
Local [spco]
plasma concentration [qnco]
Type [qlco]
plasminogen activator activity [moft]
Approach [spco]
Seen [qlco]
Systemic Therapy [topp]
Thrombolytic [phsu]
Acute myocardial infarction [dsyn]
This [euka]
Contribute [acty]
Primary [qlco]
Mechanism [ftcn]
Ischaemic [ftcn]
effects [qlco]
Associated [qlco]
Long-term [tmco]
Angiotensin converting enzyme inhibitor therapy [topp]
